Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Amortization of Deferred Charges (2023 - 2025)

Kura Oncology (KURA) has disclosed Amortization of Deferred Charges for 3 consecutive years, with $103000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Amortization of Deferred Charges fell 26.43% to $103000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $515000.0, a 1.53% decrease, with the full-year FY2025 number at $515000.0, down 1.53% from a year prior.
  • Amortization of Deferred Charges was $103000.0 for Q4 2025 at Kura Oncology, down from $141000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $141000.0 in Q3 2025 to a low of $103000.0 in Q4 2025.
  • A 3-year average of $126250.0 and a median of $124500.0 in 2023 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: rose 17.65% in 2024, then fell 26.43% in 2025.
  • Kura Oncology's Amortization of Deferred Charges stood at $119000.0 in 2023, then increased by 17.65% to $140000.0 in 2024, then decreased by 26.43% to $103000.0 in 2025.
  • Per Business Quant, the three most recent readings for KURA's Amortization of Deferred Charges are $103000.0 (Q4 2025), $141000.0 (Q3 2025), and $138000.0 (Q2 2025).